Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01740492 · ClinicalTrials.gov registry record · Phase 1

Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department

A Phase 1 study of Pain, sponsored by Rhode Island Hospital.

Completed
Registry status
Phase 1
Development phase
75
Enrollment target
1
Study location

NCT01740492 is a Phase 1 study of Pain that has completed, run by Rhode Island Hospital. The registered enrollment target is 75 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01740492, a Phase 1 study of Pain, has completed, sponsored by Rhode Island Hospital.

COMPLETED
Registry status
Phase 1
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

This study aims to address both the management and evaluation of pain. The primary aim of this study is to determine the efficacy of low dose ketamine in adults with moderate to severe pain in the emergency department as compared with parenteral opioids alone. Another aim is to examine the safety of low dose ketamine compared to opioids alone. The investigators hypothesize that low dose ketamine will result in more effective pain control than morphine alone and will not be associated with an increase in adverse events.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Ketamine 0.15mg/kg
  • DRUG Ketamine 0.3mg/kg

Study Locations (1)

Rhode Island

  • Rhode Island Hospital - Providence

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2012-09
Est. Completion 2014-06
Phase Phase 1

Sponsor

Rhode Island Hospital

130 total trials

What the Registry Record Tells You About NCT01740492

The ClinicalTrials.gov registry entry for NCT01740492 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (75% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01740492 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT01740492 about?

NCT01740492 is a clinical study titled "Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department". This study aims to address both the management and evaluation of pain. The primary aim of this study is to determine the efficacy of low dose ketamine in adults with moderate to severe pain in the emergency department as compared with parenteral opioids alone. Another aim is to examine the safety of...

What is the current status of trial NCT01740492?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2012-09. Estimated completion is 2014-06.

What conditions does trial NCT01740492 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT01740492?

The interventions under investigation include: Placebo (OTHER), Ketamine 0.15mg/kg (DRUG), Ketamine 0.3mg/kg (DRUG).

Who is sponsoring clinical trial NCT01740492?

This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01740492 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.